Functionalized Terpolymer-Brush-Based Biointerface with Improved Antifouling Properties for Ultra-Sensitive Direct Detection of Virus in Crude Clinical Samples.
Biofouling
Biological Assay
Biosensing Techniques
COVID-19
/ diagnosis
COVID-19 Testing
Coronavirus Nucleocapsid Proteins
/ chemistry
Humans
Ions
Limit of Detection
Mass Spectrometry
Nasal Mucosa
/ virology
Nasopharynx
/ virology
Phosphoproteins
/ chemistry
Polymers
/ chemistry
RNA, Viral
/ metabolism
Reproducibility of Results
Reverse Transcriptase Polymerase Chain Reaction
SARS-CoV-2
Sensitivity and Specificity
Specimen Handling
SARS-CoV-2
functional coatings
piezoelectric biosensor
polymer brush
rapid detection
zwitterionic materials
Journal
ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991
Informations de publication
Date de publication:
22 Dec 2021
22 Dec 2021
Historique:
pubmed:
14
12
2021
medline:
8
1
2022
entrez:
13
12
2021
Statut:
ppublish
Résumé
New analytical techniques that overcome major drawbacks of current routinely used viral infection diagnosis methods, i.e., the long analysis time and laboriousness of real-time reverse-transcription polymerase chain reaction (qRT-PCR) and the insufficient sensitivity of "antigen tests", are urgently needed in the context of SARS-CoV-2 and other highly contagious viruses. Here, we report on an antifouling terpolymer-brush biointerface that enables the rapid and sensitive detection of SARS-CoV-2 in untreated clinical samples. The developed biointerface carries a tailored composition of zwitterionic and non-ionic moieties and allows for the significant improvement of antifouling capabilities when postmodified with biorecognition elements and exposed to complex media. When deployed on a surface of piezoelectric sensor and postmodified with human-cell-expressed antibodies specific to the nucleocapsid (N) protein of SARS-CoV-2, it made possible the quantitative analysis of untreated samples by a direct detection assay format without the need of additional amplification steps. Natively occurring N-protein-vRNA complexes, usually disrupted during the sample pre-treatment steps, were detected in the untreated clinical samples. This biosensor design improved the bioassay sensitivity to a clinically relevant limit of detection of 1.3 × 10
Identifiants
pubmed: 34902239
doi: 10.1021/acsami.1c16930
doi:
Substances chimiques
Coronavirus Nucleocapsid Proteins
0
Ions
0
Phosphoproteins
0
Polymers
0
RNA, Viral
0
nucleocapsid phosphoprotein, SARS-CoV-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM